Remus Pharmaceuticals Limited (NSE:REMUS)

Market Cap	9.40B
Revenue (ttm)	6.20B
Net Income (ttm)	290.70M
Shares Out	11.66M
EPS (ttm)	24.67
PE Ratio	32.68
Forward PE	n/a
Dividend	0.75 (0.09%)
Ex-Dividend Date	Sep 18, 2025

Volume	n/a
Average Volume	4,560
Open	n/a
Previous Close	1,962.35
Day's Range	n/a
52-Week Range	636.10 - 2,770.00
Beta	0.17
RSI	29.99
Earnings Date	Nov 10, 2025

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceuticals products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company offers tablet, hard and soft gelatine capsules, liquid and lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays and solutions, eye drops, creams, gels,...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2015
• Employees: 68
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: REMUS

Financial Performance

In 2024, Remus Pharmaceuticals's revenue was 6.20 billion, an increase of 191.33% compared to the previous year's 2.13 billion. Earnings were 290.70 million, an increase of 41.67%.